HUMANIZED COMPLEMENT 5A RECEPTOR 1 ANTIBODIES AND METHODS OF USE THEREOF
The present disclosure provides, among other things, two different formats of humanized antibodies against human complement component 5a receptor 1. The disclosure also provides a method of treating a subject having dysfunctions of C5a/C5aR1 axis pathway, including but not limited to ANCA-associated...
Saved in:
Main Authors | , , , , , , |
---|---|
Format | Patent |
Language | English Spanish |
Published |
25.09.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present disclosure provides, among other things, two different formats of humanized antibodies against human complement component 5a receptor 1. The disclosure also provides a method of treating a subject having dysfunctions of C5a/C5aR1 axis pathway, including but not limited to ANCA-associated vasculitis, comprising administering to the subject in need thereof a an effective amount of antibody or a nucleic encoding an antibodies binding to C5aR1 described herein, and wherein administering results in a decrease in symptoms associated with C5a/C5aRl associated dysfunction in the subject.
La presente descripción proporciona, entre otras cosas, dos formatos diferentes de anticuerpos humanizados contra el receptor I del componente 5a del complemento humano. La descripción también proporciona un método para tratar a un sujeto que tiene disfunciones de la vía del eje C5a/C5aR1, que incluyen, pero sin limitarse a, vasculitis asociada a ANCA, que comprende administrar al sujeto que lo necesita una cantidad efectiva de anticuerpo o un nucleico que codifica unos anticuerpos que se unen a C5aR1 descritos en la presente descripción, y en donde la administración da como resultado una disminución de los síntomas asociados con la disfunción asociada a C5a/C5aR1 en el sujeto. |
---|---|
Bibliography: | Application Number: MX20230008302 |